News | May 10, 2021
Remdesivir allocation made upto 16th May: Gowda
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
The production capacity is now ramped up to 90 lakh vials per month whereas earlier it was 40 lakh vials/month
The Department of Pharmaceuticals launched the PLI scheme for promoting domestic manufacturing of bulk drugs, with a financial outlay of Rs. 6,940 crore across 53 APIs over 6 years
TCPCL is the largest and only commercial manufacturer of SDAs for zeolites in India
Integration of various regulatory agencies with a single-window system and putting in place a transparent, stable, predictable and easy to navigate interface.
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
Vivimed strategy is to increase its share of Branded products in CIS Markets.
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
Subscribe To Our Newsletter & Stay Updated
